Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care

Summary

Clinical Decision Support Systems (CDSSs) to augment clinical care and decision making. These are platforms which aim to improve healthcare delivery by enhancing medical decisions with targeted clinical knowledge, patient information, and other health information. In view of the benefit of developing a CDSS, we sought to develop an alternative CDSS for oncologic therapy selection through a partnership with Ping An Technology (Shenzhen, China), beginning with gastric and oesophagal cancer. This would be done in a piecemeal fashion, with the prototype platform utilizing only international guidelines and high-quality published evidence from journals to arrive at case-specific treatment recommendations. This platform would then be evaluated by comparing its recommendations with that from the multidisciplinary tumour boards of several tertiary care institutions to determine the concordance rate.

Eligibility

A. In discovery and internal retrospective validation part:

1. Patients with primary gastric adenocarcinoma including preinvasive carcinoma or
2. Patients with gastroesophageal junction cancers or
3. Patients with oesophageal cancer including adenocarcinoma, squamous cell carcinoma and preinvasive carcinoma subtypes.

B. In prospective validation part:

1. Patients with primary gastric adenocarcinoma including preinvasive carcinoma or
2. Patients with esophageal or gastroesophageal junction adenocarcinoma

Exclusion Criteria:

A. In discovery and internal retrospective validation part:

1. Patients with other primary cancers involving the stomach or oesophagus
2. Patients with other cancer subtypes
3. Patients with concomitant cancers of other organs

B. In prospective validation part:

1. Patients with esophageal squamous cell carcinoma
2. Patients who participate in clinical trials where the treatment modality is not standard of care

Conditions4

Browse More Trials